新活素联合左西孟旦治疗急性心肌梗死合并心源性休克的效果  

Effect of rhBNP Combined with Levosimendan in the Treatment of Acute Myocardial Infarction Complicated with Cardiogenic Shock

作　　者：高艺宾 江亦斌 邱陆阵[1] GAO Yibin;JIANG Yibin;QIU Luzhen(Department of Internal Medicine,Zhangzhou Municipal Hospital of Fujian Province,Zhangzhou 363100,Fujian,China;Health Management Center,Zhangzhou Municipal Hospital of Fujian Province,Zhangzhou 363100,Fujian,China)

机构地区：[1]福建省漳州市医院内科监护室,福建漳州363100 [2]福建省漳州市医院健康管理中心,福建漳州363100

出　　处：《中国药物滥用防治杂志》2024年第12期2260-2261,2268,共3页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：福建医科大学启航基金(编号:2023QH1338)。

摘　　要：目的:比较左西孟旦联合新活素与单用左西孟旦对急性心肌梗死(AMI)合并心源性休克(CS)治疗效果的影响。方法:回顾性分析2021年9月1日—2023年3月30日漳州市医院内科监护室收治的122例AMI合并CS患者,根据治疗方法不同分为联合组与对照组。对照组给予左西孟旦治疗,联合组在对照组基础上联合新活素治疗,比较两组治疗7 d后总有效率、左心室舒张末期内径、左心室收缩末期内径、心肌耗氧量以及治疗6个月的主要心血管事件发生率。结果:治疗7 d后,联合组总有效率高于对照组(P<0.05);联合组左心室舒张末期内径与左心室收缩末期内径低于对照组(P<0.05);联合组心肌耗氧量低于对照组(P<0.05)。联合组治疗6个月的主要心血管事件发生率低于对照组(P<0.05)。结论:左西孟旦联合新活素治疗AMI合并CS能提高疗效,能降低患者的左心室舒张末期内径与左心室收缩末期内径,同时可降低心肌耗氧量、主要心血管事件发生率,值得临床借鉴。Objective:To compare the effect of levosimendan combined with rhBNP and levosimendan alone on the treatment of acute myocardial infarction(AMI)complicated with cardiogenic shock(CS).Method:A retrospective analysis of 122 patients with AMI complicated with CS admitted to the Department of Internal Medicine of Zhangzhou Hospital from September 1,2021 to March 30,2023 was divided into combined group and control group according to different treatment methods.The control group was treated with levosimendan,and the combined group was treated with neomycin on the basis of the control group.The total effective rate,left ventricular end-diastolic diameter,left ventricular end-systolic diameter,myocardial oxygen consumption and the incidence of major cardiovascular events at 6 months after treatment were compared between the two groups.Results:After 7 days of treatment,the total effective rate of the combined group was higher than that of the control group(P<0.05);the left ventricular end-diastolic diameter and left ventricular end-systolic diameter in the combined group were lower than those in the control group(P<0.05);the myocardial oxygen consumption in the combined group was lower than that in the control group(P<0.05).The incidence of major cardiovascular events in the combined group was lower than that in the control group at 6 months of treatment(P<0.05).Conclusion:Levosimendan combined with rhBNP in the treatment of AMI combined with CS can improve the curative effect,reduce the left ventricular end-diastolic diameter and left ventricular end-systolic diameter,and reduce the myocardial oxygen consumption and the incidence of major cardiovascular events,which is worthy of clinical reference.

关 键 词：左西孟旦 新活素 急性心肌梗死合并心源性休克 左心室舒张末期内径 心肌耗氧量 主要心血管事件 

分 类 号：R54[医药卫生—心血管疾病]